UBS Group’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-751
| Closed | -$15.8K | – | 10868 |
|
|
2025
Q4 | $15.8K | Buy |
+751
| New | +$20.4K | ﹤0.01% | 7946 |
|
|
2025
Q1 | – | Sell |
-7
| Closed | -$508 | – | 10500 |
|
|
2024
Q4 | $508 | Sell |
7
-2,239
| -100% | -$137K | ﹤0.01% | 9443 |
|
|
2024
Q3 | $131K | Buy |
2,246
+1,436
| +177% | +$87.2K | ﹤0.01% | 6165 |
|
|
2024
Q2 | $59.4K | Sell |
810
-1,412
| -64% | -$119K | ﹤0.01% | 6555 |
|
|
2024
Q1 | $162K | Sell |
2,222
-987
| -31% | -$82.4K | ﹤0.01% | 5990 |
|
|
2023
Q4 | $311K | Buy |
3,209
+3,204
| +64,080% | +$623K | ﹤0.01% | 5469 |
|
|
2023
Q3 | $1.09K | Sell |
5
-2,465
| -100% | -$400K | ﹤0.01% | 8109 |
|
|
2023
Q2 | $355K | Buy |
2,470
+1,541
| +166% | +$230K | ﹤0.01% | 5094 |
|
|
2023
Q1 | $191K | Buy |
929
+28
| +3% | +$4.76K | ﹤0.01% | 5413 |
|
|
2022
Q4 | $155K | Sell |
901
-903
| -50% | -$185K | ﹤0.01% | 5695 |
|
|
2022
Q3 | $432K | Buy |
1,804
+947
| +111% | +$220K | ﹤0.01% | 4469 |
|
|
2022
Q2 | $333K | Sell |
857
-2,314
| -73% | -$1.16M | ﹤0.01% | 4567 |
|
|
2022
Q1 | $1.11M | Buy |
3,171
+3,050
| +2,521% | +$1.2M | ﹤0.01% | 3983 |
|
|
2021
Q4 | $31K | Sell |
121
-215
| -64% | -$49.4K | ﹤0.01% | 7363 |
|
|
2021
Q3 | $72K | Sell |
336
-782
| -70% | -$166K | ﹤0.01% | 6069 |
|
|
2021
Q2 | $216K | Buy |
1,118
+1,111
| +15,871% | +$249K | ﹤0.01% | 5283 |
|
|
2021
Q1 | $1K | Buy |
7
+5
| +250% | +$969 | ﹤0.01% | 8781 |
|
|
2020
Q4 | $1K | Buy |
+2
| New | +$763 | ﹤0.01% | 8227 |
|
|
2020
Q2 | – | Hold |
0
| – | -$1K | – | 8165 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7771 |
|
|
2019
Q4 | – | Sell |
-15
| Closed | -$76K | – | 8279 |
|
|
2019
Q3 | $76K | Buy |
15
+7
| +88% | +$28.8K | ﹤0.01% | 5931 |
|
|
2019
Q2 | $29K | Hold |
8
| – | – | ﹤0.01% | 6358 |
|
|
2019
Q1 | $31K | Buy |
+8
| New | +$38.7K | ﹤0.01% | 5915 |
|
|
2018
Q4 | – | Sell |
-15
| Closed | -$75K | – | 8171 |
|
|
2018
Q3 | $75K | Buy |
+15
| New | +$72.4K | ﹤0.01% | 5828 |
|
|
2018
Q2 | – | Sell |
-2
| Closed | -$15K | – | 8125 |
|
|
2018
Q1 | $15K | Buy |
+2
| New | +$13.9K | ﹤0.01% | 6614 |
|
|
2017
Q3 | – | Sell |
-2
| Closed | -$34K | – | 7868 |
|
|
2017
Q2 | $34K | Buy |
+2
| New | +$38.4K | ﹤0.01% | 5926 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | -$56K | – | 7808 |
|
|
2016
Q4 | $56K | Hold |
1
| – | – | ﹤0.01% | 5732 |
|
|
2016
Q3 | $38K | Hold |
1
| – | – | ﹤0.01% | 5730 |
|
|
2016
Q2 | $60K | Buy |
+1
| New | +$80.6K | ﹤0.01% | 5380 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | -$39K | – | 7921 |
|
|
2015
Q4 | $39K | Hold |
1
| – | – | ﹤0.01% | 6057 |
|
|
2015
Q3 | $71K | Buy |
+1
| New | +$70.8K | ﹤0.01% | 5503 |
|
Other funds holding LABD
IC
CCM
CF
GS
UBS Group's LABD Position: Q1 2026 in Review
UBS Group sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026, closing a stake of 751 shares — an estimated $15.8K sold.
UBS Group first reported a position in LABD in Q3 2015 and held it in 29 quarters. The position peaked at $1.11M in Q1 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.
- UBS Group reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 751 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $15.8K.
- UBS Group first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2015 and held it in 29 quarters.
- UBS Group's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $1.11M in Q1 2022.
- 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.